CaltechAUTHORS
Published November 2020 | Version Published
Journal Article Open

Sequential multi-locus transcranial magnetic stimulation for treatment of obsessive-compulsive disorder with comorbid major depression: A case series

Creators

  • 1. ROR icon UCLA Health
  • 2. ROR icon California Institute of Technology
  • 3. ROR icon University of California, Los Angeles

Abstract

Obsessive-compulsive disorder (OCD) and major depressive disorder (MDD) are highly comorbid [1], with depressive symptoms amplifying the chronicity and severity of OCD symptoms. Comorbid illness decreases quality of life and daily functioning [2] and is associated with greater suicidality and more frequent inpatient hospitalizations [3]. Furthermore, comorbid OCD/depression is associated with poorer response to OCD-focused psychological and pharmacological treatments [4]. Epidemiologic studies have shown that OCD symptoms generally precedes the occurrence of depression, suggesting a causal interacting model in which OCD predisposes to development of depressive symptoms [5]. In line with that causal model, Tadayonnejad et al. showed aberrant effective (directional) connectivity between OCD and MDD circuits may be a potential network mechanism of depressive symptom genesis or worsening in OCD-MDD [6]. The challenging nature of this comorbidity necessitates the development of novel, more effective treatments.

Additional Information

© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Received 5 September 2020, Revised 6 October 2020, Accepted 11 October 2020, Available online 13 October 2020. Declaration of competing interest: The authors declare no conflict of interest. Mr. Wilson has served as a consultant to HeartCloud, Inc. Dr. Leuchter has received research support from the CHDI Foundation, the Department of Defense, Neuronetics, NeuroSigma, and NIH; he has served as a consultant to ElMindA, Ionis Pharmaceuticals, and NeoSync; and, he is chief scientific officer of and has equity interest in Brain Biomarker Analytics. The rest of authors report no financial relationships with commercial interests.

Attached Files

Published - 1-s2.0-S1935861X20302709-main.pdf

Files

1-s2.0-S1935861X20302709-main.pdf

Files (386.6 kB)

Name Size
md5:7a8ff91fcaae72daaf023c7f11427a3d
386.6 kB Preview Download

Additional details

Identifiers

Eprint ID
106292
Resolver ID
CaltechAUTHORS:20201027-084250087

Funding

CHDI Foundation
Department of Defense
Neuronetics
NeuroSigma
NIH

Dates

Created
2020-10-27
Created from EPrint's datestamp field
Updated
2021-11-16
Created from EPrint's last_modified field